<DOC>
	<DOCNO>NCT02025192</DOCNO>
	<brief_summary>The purpose study determine maximal tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) ONT-380 ass safety tolerability ONT-380 combine capecitabine alone , trastuzumab alone capecitabine trastuzumab patient HER2+ metastatic breast cancer .</brief_summary>
	<brief_title>A Phase 1b Study ONT-380 Combined With Capecitabine and/or Trastuzumab Patients With HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase 1b , open-label study ONT-380 give combination capecitabine alone , trastuzumab alone capecitabine trastuzumab patient HER2+ metastatic breast cancer . Phase 1 use 3+3 dose escalation design evaluate escalate dose level ONT-380 three combination order identify maximal tolerate dose/recommended phase 2 dose ( MTD/RP2D ) ONT-380 . Capecitabine give 1000 mg/m2 PO BID Days 1-14 21-day cycle . Trastuzumab give load dose 8 mg/kg IV follow 6 mg/kg every 21 day . However , load dose trastuzumab give patient receive trastuzumab within 4 week first study dose trastuzumab . These patient receive trastuzumab 6 mg/kg cycle , include Cycle 1 . Trastuzumab may also give weekly basis 2 mg/kg IV q 7 day , circumstance trastuzumab infusion delay , weekly infusion require resynchronize cycle length 21 day , discussion medical monitor . Trastuzumab infusion rate per institutional guideline . ONT-380 give PO BID dose dependent upon dose cohort patient enrol . There 3-6 evaluable patient enrol cohort dose escalation phase , unless dose find intolerable prior completion enrollment . At least 6 evaluable patient treat dose level order MTD/RP2D determine . The MTD/RP2D ONT-380 use combination either capecitabine alone ( Combination 1 ) trastuzumab alone ( Combination 2 ) determine prior evaluate ONT-380 combination capecitabine trastuzumab ( Combination 3 ) . If Combination 1 Combination 2 find tolerable , ONT-380 evaluate Combination 3 , use low MTD/RP2D SMC-recommended dose ONT-380 determine either two drug combination . This follow enrollment expansion cohort patient treat MTD/RP2D Combination 3 . Additional expansion cohort either Combination 1 ( ONT-380 capecitabine ) Combination 2 ( ONT-380 trastuzumab ) may also enrol . Provided seven dose cohort need dose escalation expansion cohort Combination 3 enrol , 66 evaluable patient may enrol . Additional patient may enrol additional expansion cohort open .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion Criteria Patients must meet follow criterion eligible study : 1 . Metastatic breast cancer , document HER2+ fluorescence situ hybridization ( FISH ) and/or 3+ stain immunohistochemistry ( IHC ) . 2 . Progressive disease , history prior treatment trastuzumab TDM1 ( unless deem intolerant ineligible TDM1 investigator ) metastatic disease . 3 . ≥ 18 year time consent . 4 . If female childbearing potential , negative pregnancy test within 14 day prior treatment . 5 . If sexually active male sexually active female childbearing potential , agree use dual ( two concurrent ) form medically accept contraception time consent 6 month last dose ONT380 , capecitabine , trastuzumab , whichever long . 6 . Signed informed consent document approve institutional review board independent ethic committee ( IRB/IEC ) . 7 . Must target nontarget lesion per Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 . 8 . All toxicity relate prior cancer therapy must resolve ≤ Grade 1 , follow exception : alopecia ; neuropathy , must resolve ≤ Grade 2 ; congestive heart failure ( CHF ) , must ≤ Grade 1 severity time occurrence must resolve completely . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screening . 10 . In opinion Investigator , life expectancy &gt; 6 month . 11 . Adequate hematologic function define : 1 . Hemoglobin ≥ 9 g/dL 2 . Absolute neutrophil count ( ANC ) ≥ 1000 cells/μL 3 . Platelets ≥ 100,000/μL 12 . Adequate hepatic function define follow : 1 . Total bilirubin ≤ 1.5 X upper limit normal ( ULN ) , unless know history Gilbert 's disease 2 . Transaminases ( aspartate aminotransferase/serum glutamic oxaloacetic transaminase [ AST/SGOT ] alanine aminotransferase/serum glutamic pyruvic transaminase [ ALT/SGPT ] ) ≤ 2.5 X ULN ( &lt; 5 X ULN liver metastasis present ) 13. International normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) ≤ 1.5 X ULN unless medication know alter INR aPTT . 14 . Creatinine clearance ≥ 50 mL/min . 15 . Left ventricular ejection fraction ( LVEF ) must within institutional limit normal assessed echocardiogram ( ECHO ) multiplegated acquisition scan ( MUGA ) document within 4 week prior first dose study drug . Exclusion Criteria Patients exclude study follow reason : 1 . Medical , social , psychosocial factor , opinion Investigator , could impact safety compliance study procedure . 2 . Patient breastfeeding . 3 . Previous treatment experimental agent within 14 day five halflives study treatment , whichever great . 4 . Previous treatment trastuzumab antibodybased therapy within three week start study treatment chemotherapy hormonal cancer therapy within two week start study treatment . 5 . Previous treatment cumulative dose doxorubicin &gt; 360 mg/m2 previous treatment another anthracycline cumulative dose equivalent &gt; 360 mg/m2 doxorubicin . 6 . Previous treatment : 1 . Capecitabine metastatic disease time , patient assign cohort use capecitabine plus ONT380 ( Combination 1 ) capecitabine plus trastuzumab plus ONT380 ( Combination 3 ) . However , patient previous treatment capecitabine metastatic disease eligible enrollment cohort use trastuzumab plus ONT380 ( Combination 2 ) . Patients receive capecitabine adjuvant neoadjuvant treatment least 12 month prior start study treatment eligible enroll cohort ( Combination 1 , 2 , 3 ) . 2 . Any small molecule HER2 inhibitor include ( limited ) lapatinib , neratinib , afatinib within last 4 week prior initiation study therapy . 7 . CNS disease : 1 . Patients leptomeningeal disease exclude . 2 . Dose escalation expansion cohort : Patients symptomatic CNS metastasis exclude . Patients treat CNS metastasis untreated asymptomatic CNS metastasis require immediate local therapy may eligible . Enrollment patient metastases must approve study medical monitor . 3 . Optional CNS disease expansion cohort : Patients untreated asymptomatic CNS metastasis require immediate local therapy patient progressive CNS disease follow local therapy may eligible medical monitor approval . 8 . History allergic reaction compound similar chemical biological composition capecitabine ( patient assign Combination 1 3 ) , trastuzumab ( patient assign Combination 2 3 ) , ONT380 , except history Grade 1 Grade 2 Infusion Related Reaction trastuzumab , successfully manage . 9 . Patients uncorrectable electrolyte abnormality . 10 . Known HIV positive . HIV test required patient know positive . 11 . Known carrier Hepatitis B / Hepatitis C ( whether active disease ) . 12 . Known liver disease , autoimmune hepatitis , sclerosing cholangitis . 13 . Inability swallow pill significant gastrointestinal disease , would preclude adequate absorption oral medication . 14 . Use strong CYP3A4 inhibitor inducer within three elimination halflives inhibitor inducer prior start study treatment . 15 . Use strong CYP2C8 inducer inhibitor within three elimination halflives inducer inhibitor prior start study treatment . ( See Appendix F ) . 16 . Radiotherapy within 14 day first dose ONT380 ; patient must recover acute effect radiotherapy baseline . 17 . Known impaired cardiac function clinically significant cardiac disease ventricular arrhythmia require therapy , congestive heart failure , uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . 18 . Myocardial infarction unstable angina within 6 month prior first dose study drug . 19 . Patient known dihydropyrimidine dehydrogenase deficiency ( patient assign Combination 1 3 ) . 20 . Patient require warfarin therapy know history difficulty management maintain INR within therapeutic range . Patients warfarin may include stable dose therapeutic INR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ONT-380</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Herceptin</keyword>
	<keyword>HER2 positive breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>ARRY-380</keyword>
	<keyword>Tucatinib</keyword>
</DOC>